- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01282957
Way to Health, Healthy Measures
Financial Incentives for Home-based Health Management: A Pilot Randomized Trial
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
While home monitoring of health appears to be a promising frontier in health care, patient adherence to, and utilization of, such devices is often low, limiting the potential benefit of this technology. Financial incentives have been effective in increasing rates of weight loss, smoking cessation, and medication adherence and therefore may increase rates of utilization of home-based health monitoring devices. Therefore, in this study, we test the effects of lottery-based incentives on use of home-based health monitoring technologies.
The aim of this pilot randomized controlled trial is to evaluate whether financial incentives delivered through a novel online platform can effectively increase use of home-based health monitoring technology among overweight adults with diabetes. Our primary objective is to assess the effects of financial incentives on the use of home health monitoring devices among high-risk patients. In addition, we have three secondary objectives: (1) obtain preliminary evidence regarding whether the monetary value of incentives has a differential effect on the use of home health monitoring devices; (2) identify potential barriers that prohibit regular use of home-based health devices using qualitative data; and (3) assess the usability of a newly developed web portal and its feasibility for future randomized clinical trials aimed at changing health-related behaviors.
Participants will be randomized into each of the following three arms: (1) Financial Incentive Group I; (2) Financial Incentive Group II; (3) Control Group. Incentives for Financial Groups I and II are designed in a way that builds on the success of previous incentive-based interventions for weight loss. Both lotteries are tailored to provide infrequent large payoffs and frequent small payoffs since lottery players are motivated by both the possibility of a large reward and the opportunity for regular, immediate rewards. The average expected payoff value of Financial Incentive Group I will be $2.80 per day and $1.40 per day in Financial Incentive Group II. The interventions will run for 91 days starting at randomization. At the end of the intervention time period, each participant will be notified that the intervention period has ended and the 90-day follow-up period has begun. During the follow-up period each participant will continue to upload measurements daily, but will not receive incentives or reminders.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- University of Pennsylvania
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults between 18 and 80 years of age
- Hemoglobin A1c measured in the last six weeks greater than or equal to 7.5%
- Weight less than 425lbs
- Cell phone with text messaging capabilities or email access
- Followed by Primary Care Provider at Penn Internal Medicine Associates practice at 3701 Market St
Exclusion Criteria:
- Lack or are unwilling to use email or cell phone for text messaging
- Are enrolled in other, ongoing clinical trials
- Suffer from an uncontrolled psychiatric disease
- Have a history or diagnosis of heart failure as confirmed by ICD-9 codes: 428.0 (congestive heart failure), 425.0 (cardiomyopathy), and 414.8 ischemic cardiomyopathy)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Active Control
Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 6 months
|
|
|
Eksperimentell: Financial Incentive Group I
Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months.
If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $100 and 2 in 10 odds of winning $10.
Financial incentive terminated after 3 months.
Daily use of devices continues for additional 3 months.
(Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
|
Lottery with 1 in 100 odds of $100 and 18 in 100 odds of $10.
The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
|
|
Eksperimentell: Financial Incentives Group II
Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months.
If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $50 and 2 in 10 odds of winning $5. Financial incentive terminated after 3 months.
Daily use of devices continues for additional 3 months.
(Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
|
Lottery with 1 in 100 odds of $50 and 18 in 100 odds of $5.
The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate of use of the three home-based technologies
Tidsramme: 3-months
|
We will analyze the proportion of days that home monitoring was completed (defined as successful reporting of data from all three devices - weight, blood pressure and blood sugar) compared to failure to report across all groups after the end of the 3-month intervention period.
|
3-months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Usability and functionality of the study's online web portal, Way to Health, and wifi-enabled home health monitoring devices
Tidsramme: 6-months
|
We will ask participants to participate in a qualitative interview at the final study visit to assess the usability and functionality of the web portal and study devices for use during future studies.
|
6-months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Volpp KG, John LK, Troxel AB, Norton L, Fassbender J, Loewenstein G. Financial incentive-based approaches for weight loss: a randomized trial. JAMA. 2008 Dec 10;300(22):2631-7. doi: 10.1001/jama.2008.804.
- Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, Galvin R, Zhu J, Wan F, DeGuzman J, Corbett E, Weiner J, Audrain-McGovern J. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med. 2009 Feb 12;360(7):699-709. doi: 10.1056/NEJMsa0806819.
- Volpp KG, Loewenstein G, Troxel AB, Doshi J, Price M, Laskin M, Kimmel SE. A test of financial incentives to improve warfarin adherence. BMC Health Serv Res. 2008 Dec 23;8:272. doi: 10.1186/1472-6963-8-272.
- Sen AP, Sewell TB, Riley EB, Stearman B, Bellamy SL, Hu MF, Tao Y, Zhu J, Park JD, Loewenstein G, Asch DA, Volpp KG. Financial incentives for home-based health monitoring: a randomized controlled trial. J Gen Intern Med. 2014 May;29(5):770-7. doi: 10.1007/s11606-014-2778-0. Epub 2014 Feb 13.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 812211
- RC2AG036592 (U.S. NIH-stipend/kontrakt)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hypertensjon
-
University Hospital of CologneUkjentNAFLD; Hypertensjon, White-Coat Hypertension, Masked HypertensionTyskland
-
University Hospital, CaenHar ikke rekruttert ennåWhite Coat Hypertension
-
Karolinska InstitutetFullførtWhite Coat Hypertension
-
Clinical Hospital Centre ZagrebEuropean Society of HypertensionUkjentWhite Coat Hypertension | Blodtrykk | LivsstilsrisikoreduksjonIsrael, Hellas, Belgia, Tyskland, Armenia, Østerrike, Bulgaria, Kroatia, Tsjekkia, Estland, Italia, Libanon, Litauen, Nederland, Polen, Portugal, Romania, Serbia, Spania, Sverige, Ukraina, Storbritannia
-
Columbia UniversityWeill Medical College of Cornell University; Agency for Healthcare Research...FullførtWhite Coat Hypertension | Hypertensjon, viktigForente stater
-
Regional Hospital HolstebroFullførtSunn | White Coat Hypertension | Essensiell hypertensjonDanmark
-
University of Alabama at BirminghamTroy UniversityFullførtHypertensjon | Hypertensjon, motstandsdyktig mot konvensjonell terapi | Ukontrollert hypertensjon | Hypertensjon, hvit pelsForente stater
-
PD Dr. Grégoire WuerznerSwiss National Science FoundationFullførtHypertensjon | Overvekt | White Coat Hypertension | Resistent hypertensjonSveits
-
Mayo ClinicFullførtHypertensjon | Angst | White Coat Hypertension | Blodtrykk | Blodtrykksforstyrrelser | Ambulant blodtrykksovervåking | Virtual Reality eksponeringsterapiForente stater
-
University Hospital, ToursFullførtPTFE-dekkede stenter versus nakne stenter i TIPS (Transjugulær Intra-hepatisk Porto-systemisk shunt)Cirrhotic Portal HypertensionFrankrike
Kliniske studier på Financial Incentive Group I
-
University of California, Los AngelesEunice Kennedy Shriver National Institute of Child Health and Human Development...Påmelding etter invitasjonBarneutvikling | Mental HelseForente stater
-
University of OklahomaMcMaster University; University of Georgia; University of KentuckyRekruttering
-
Indiana Institute for Medical ResearchGenentech, Inc.; Regenstrief Institute, Inc.; Richard L. Roudebush VA Medical...Fullført
-
Cairo UniversityEl-Sahel Teaching Hospital; National Hepatology & Tropical Medicine Research...Fullført
-
University of PennsylvaniaFullførtLeddgikt, revmatoid | Leddgikt, psoriasisForente stater
-
Chestnut Health SystemsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Fullført
-
Yonsei UniversityFullførtCerebral pareseKorea, Republikken
-
McMaster UniversityMcMaster Surgical AssociatesFullførtLungeneoplasmer | Godartet lungesykdomCanada
-
Singapore National Eye CentreFullført
-
Washington University School of MedicineColumbia University; Makerere UniversityRekrutteringHIV-forebyggingUganda, Forente stater